文献速递创伤与烧伤复苏、休克与脓毒症

严重创伤中基于黏弹性检测动态使用纤维蛋白原可减少血浆用量并降低总体输血需求

Dynamic use of fibrinogen under viscoelastic assessment results in reduced need for plasma and diminished overall transfusion requirements in severe trauma.
PubMed 文献 · J Trauma Acute Care Surg · 2022-03-28
一句话结论严重创伤患者采用旋转血栓弹力测定指导、仅用纤维蛋白原浓缩物的无血浆策略,可减少红细胞、血浆和血小板输注,并降低肺炎和多器官衰竭发生率。

该研究纳入2008年1月至2019年7月共135例严重创伤患者,按输血策略演变分为血浆组(P,n=28)、血浆+纤维蛋白原浓缩物组(PF,n=64)和仅纤维蛋白原浓缩物组(F,n=42)。随旋转血栓弹力测定逐步实施,纤维蛋白原浓缩物使用增加(p<0.001)。回归分析显示F组红细胞输注(p=0.005)、血浆输注(p<0.001)和血小板输注(p=0.011)均显著减少。F组肺炎(p=0.019)和多器官衰竭(p<0.001)更少,总体死亡率无显著差异,但仅因大出血导致的死亡率F组较所有接受血浆的患者显著降低(p=0.037)。

要点

  • 在严重创伤患者中,逐步实施旋转血栓弹力测定指导的止血复苏使纤维蛋白原浓缩物使用随时间增加(p<0.001)。
  • 仅用纤维蛋白原浓缩物组较其他组显著减少红细胞输注(p=0.005)、血浆输注(p<0.001)和血小板输注(p=0.011)。
  • 仅用纤维蛋白原浓缩物组肺炎发生率更低(p=0.019)、多器官衰竭更少(p<0.001),总体死亡率无显著差异。
  • 仅因大出血导致的死亡率在仅用纤维蛋白原浓缩物组显著低于所有接受血浆的患者(p=0.037)。
  • 该无血浆策略未增加血栓并发症。

适用人群与场景

  • 2008年1月至2019年7月收治的135例严重创伤患者,均因高能量损伤机制、出血严重程度和血流动力学不稳定而需初始评估创伤性凝血病高风险。
  • 按输血策略演变分为三组:血浆组(P,n=28)、血浆+纤维蛋白原浓缩物组(PF,n=64)、仅纤维蛋白原浓缩物组(F,n=42)。

处置流程与药物剂量

  • 本研究中心的做法是:以旋转血栓弹力测定为指导的黏弹性止血检测实施目标导向的复苏方案,随时间逐步从血浆策略过渡到血浆+纤维蛋白原浓缩物,再到仅用纤维蛋白原浓缩物。

研究设计与关键结果

  • 研究类型为单中心队列研究,纳入135例严重创伤患者,按输血策略演变分为血浆组(n=28)、血浆+纤维蛋白原浓缩物组(n=64)和仅纤维蛋白原浓缩物组(n=42)。
  • 三组基线特征无显著差异。
  • 随旋转血栓弹力测定逐步实施,纤维蛋白原浓缩物使用随时间增加(p<0.001)。
  • 回归分析显示,仅纤维蛋白原浓缩物组较其他组显著减少红细胞输注(p=0.005)、血浆输注(p<0.001)和血小板输注(p=0.011)。
  • 仅纤维蛋白原浓缩物组肺炎更少(p=0.019)、多器官衰竭更少(p<0.001),其他结局无显著差异。
  • 总体死亡率无显著差异;仅因大出血导致的死亡率在仅纤维蛋白原浓缩物组显著低于所有接受血浆的患者(p=0.037)。
  • 未观察到血栓并发症增加。

证据类型、等级与局限

  • 证据类型:治疗/护理管理研究,证据等级IV级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在严重创伤合并创伤性凝血病高风险患者中,实施基于黏弹性止血检测(旋转血栓弹力测定)的目标导向复苏方案,采用无血浆策略并增加纤维蛋白原浓缩物使用,可减少红细胞、血浆和血小板输注,且未增加血栓并发症。
  • 该策略可能降低肺炎和多器官衰竭发生率,并可能降低仅因大出血导致的死亡率,但总体死亡率无显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite advances in trauma management, half of trauma deaths occur secondary to bleeding. Currently, hemostatic resuscitation strategies consist of empirical transfusion of blood products in a predefined fixed ratio (1:1:1) to both treat hemorrhagic shock and correct trauma-induced coagulopathy. At our hospital, the implementation of a resuscitation protocol guided by viscoelastic hemostatic assays (VHAs) with rotational thromboelastometry has resulted in a goal-directed approach. The objective of the study is twofold, first to analyze changes in transfusion practices overtime and second to identify the impact of these changes on coagulation parameters and clinical outcomes. We hypothesized that progressive VHA implementation results in a higher administration of fibrinogen concentrate (FC) and lower use of blood products transfusion, especially plasma.

METHODS: A total of 135 severe trauma patients (January 2008 to July 2019), all requiring and initial assessment for high risk of trauma-induced coagulopathy based on high-energy injury mechanism, severity of bleeding and hemodynamic instability were included. After 2011 when we first modified the transfusion protocol, a progressive change in transfusional management occurred over time. Three treatment groups were established, reflecting different stages in the evolution of our strategy: plasma (P, n = 28), plasma and FC (PF, n = 64) and only FC (F, n = 42).

RESULTS: There were no significant differences in baseline characteristics among groups. Progressive implementation of rotational thromboelastometry resulted in increased use of FC over time ( p < 0.001). Regression analysis showed that group F had a significant reduction in transfusion of packed red blood cells ( p = 0.005), plasma ( p < 0.001), and platelets ( p = 0.011). Regarding outcomes, F patients had less pneumonia ( p = 0.019) and multiorgan failure ( p < 0.001), without significant differences for other outcomes. Likewise, overall mortality was not significantly different. However, further analysis comparing specific mortality due only to massive hemorrhage in the F group versus all patients receiving plasma, it was significantly lower ( p = 0.037).

CONCLUSION: Implementing a VHA-based algorithm resulted in a plasma-free strategy with higher use of FC and a significant reduction of packed red blood cells transfused. In addition, we observed an improvement in outcomes without an increase in thrombotic complications.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Barquero López M, Martínez Cabañero J, Muñoz Valencia A, et al. Dynamic use of fibrinogen under viscoelastic assessment results in reduced need for plasma and diminished overall transfusion requirements in severe trauma. J Trauma Acute Care Surg. 2022. PMID: 35358159. doi:10.1097/TA.0000000000003624

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。